BioCryst Pharmaceuticals Stock Options

BCRX Stock  USD 7.31  0.18  2.40%   

BioCryst Pharmaceuticals Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

BioCryst Total Stockholder Equity

Total Stockholder Equity

(432.75 Million)

BioCryst Pharmaceuticals reported Total Stockholder Equity of (455.53 Million) in 2023

BioCryst Pharmaceuticals Corporate Management

Yarlagadda BabuSr. VP of Drug DiscoveryProfile
Alane BarnesVP, General Counsel and Corporate SecretaryProfile
Elliott BergerVP AffairsProfile
William MBBSChief OfficerProfile
Stephanie AngeliniChief OfficerProfile
Michael JonesExecutive OfficerProfile
Clayton FletcherChief OfficerProfile

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.